Valley National Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Valley National Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-59	Closed	-$5K	–	911
2021 Q3	$5K	Sell	59 -7	-11%	-$552	﹤0.01%	651
2021 Q2	$6K	Buy	66 +31	+89%	+$2.46K	﹤0.01%	643
2021 Q1	$3K	Buy	+35	New	+$2.86K	﹤0.01%	682
2019 Q3	–	Sell	-63	Closed	-$5K	–	759
2019 Q2	$5K	Hold	63	–	–	﹤0.01%	547
2019 Q1	$6K	Hold	63	–	–	﹤0.01%	527
2018 Q4	$5K	Buy	+63	New	+$5.99K	﹤0.01%	518
2018 Q1	–	Sell	-17	Closed	-$2K	–	646
2017 Q4	$2K	Hold	17	–	–	﹤0.01%	542
2017 Q3	$2K	Buy	+17	New	+$1.5K	﹤0.01%	537

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Valley National Advisers's BMRN Position: Q4 2021 in Review

Valley National Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 59 shares — an estimated $5K sold.

Valley National Advisers first reported a position in BMRN in Q3 2017 and held it in 8 quarters. The position peaked at $6K in Q2 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Valley National Advisers reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Valley National Advisers sold 59 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $5K.
Valley National Advisers first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 8 quarters.
Valley National Advisers's BioMarin Pharmaceuticals position peaked at $6K in Q2 2021.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Valley National Advisers's 13F filing for Q4 2021, filed 11 Feb 2022.